Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRH Effects of Cebranopadol vs Oxycodone in Healthy Subjects
NCT05491785Phase 1Completed
- Sponsor
- Tris Pharma
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cebranopadol in pain (6 arms), sponsored by Tris Pharma. Primary endpoint: Ventilatory response to hypercapnia by maximum decrease in minute ventilation at 24 hours. Started Jul 2022; status: completed.
02
Drugs
cebranopadol
03
Conditions
pain
Beyond the preview
Go deeper on NCT05491785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491785.